Crystal growth inhibitors for the prevention of L-cystine kidney stones through molecular design

Jeffrey D. Rimer, Zhihua An, Zina Zhu, Michael H. Lee, David S. Goldfarb, Jeffrey A. Wesson, Michael D. Ward

Research output: Contribution to journalArticle

Abstract

Crystallization of L-cystine is a critical step in the pathogenesis of cystine kidney stones. Treatments for this disease are somewhat effective but often lead to adverse side effects. Real-time in situ atomic force microscopy (AFM) reveals that L-cystine dimethylester (L-CDME) and L-cystine methylester (L-CME) dramatically reduce the growth velocity of the six symmetry-equivalent {100} steps because of specific binding at the crystal surface, which frustrates the attachment of L-cystine molecules. L-CDME and L-CME produce L-cystine crystals with different habits that reveal distinct binding modes at the crystal surfaces. The AFM observations are mirrored by reduced crystal yield and crystal size in the presence of L-CDME and L-CME, collectively suggesting a new pathway to the prevention of L-cystine stones by rational design of crystal growth inhibitors.

Original languageEnglish (US)
Pages (from-to)337-341
Number of pages5
JournalScience
Volume330
Issue number6002
DOIs
StatePublished - Oct 15 2010

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Crystal growth inhibitors for the prevention of L-cystine kidney stones through molecular design'. Together they form a unique fingerprint.

Cite this